JP4025600B2 - Topical skin preparation - Google Patents
Topical skin preparation Download PDFInfo
- Publication number
- JP4025600B2 JP4025600B2 JP2002234713A JP2002234713A JP4025600B2 JP 4025600 B2 JP4025600 B2 JP 4025600B2 JP 2002234713 A JP2002234713 A JP 2002234713A JP 2002234713 A JP2002234713 A JP 2002234713A JP 4025600 B2 JP4025600 B2 JP 4025600B2
- Authority
- JP
- Japan
- Prior art keywords
- placenta
- extract
- placenta extract
- rye
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 19
- 230000000699 topical effect Effects 0.000 title description 2
- 210000002826 placenta Anatomy 0.000 claims description 84
- 239000000284 extract Substances 0.000 claims description 64
- 241000209504 Poaceae Species 0.000 claims description 4
- 235000007238 Secale cereale Nutrition 0.000 description 24
- 241000209056 Secale Species 0.000 description 23
- 241000196324 Embryophyta Species 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000006071 cream Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- -1 polyoxyethyleneoxypropylene Polymers 0.000 description 13
- 238000000605 extraction Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 239000012085 test solution Substances 0.000 description 7
- 230000002087 whitening effect Effects 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000592344 Spermatophyta Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910000365 copper sulfate Inorganic materials 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000000956 solid--liquid extraction Methods 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- OEOIWYCWCDBOPA-UHFFFAOYSA-N 6-methyl-heptanoic acid Chemical compound CC(C)CCCCC(O)=O OEOIWYCWCDBOPA-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000975394 Evechinus chloroticus Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 244000082988 Secale cereale Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- DQAKJEWZWDQURW-UHFFFAOYSA-N pyrrolidonecarboxylic acid Chemical class OC(=O)N1CCCC1=O DQAKJEWZWDQURW-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、皮膚外用剤に関する。さらに詳しくは、本発明は、優れた細胞賦活効果、美白効果、肌荒れ改善効果、育毛効果を有し、健康上の不安なく使用することができる皮膚外用剤に関する。
【0002】
【従来の技術】
脊椎動物の胎盤の抽出物であるプラセンタエキスには、顕著な薬効があることが知られており、肌荒れ改善美容剤、美白化粧料、毛髪化粧料、妊娠線形成抑制剤などの皮膚外用剤の成分として用いられるほか、健康飲料、栄養補助食品などの成分としても広く知られている。ウシ由来のプラセンタエキスは、例えば、妊娠3〜4か月の雌牛の胎盤を粉砕し、水で抽出した抽出液を遠心分離し、無菌ろ過することにより、製造することができ、市販品としても販売されている。プラセンタエキスには、アミノ酸、ペプチド、核酸、ビタミンなどが含まれる。
しかしながら、牛海綿状脳症(BSE)いわゆる狂牛病が日本でも発生したことから、動物の胎盤を原料とするプラセンタエキスの使用に対する消費者の不安が高まっている。ウシ以外の動物、例えば、ブタ由来のプラセンタエキスも入手可能ではあるが、できれば動物由来の原料は避けたいというのが消費者の偽らぬ心情である。このために、動物由来のプラセンタエキスと同様な薬効を有し、健康上の不安なく使用することができる植物由来の薬剤が求められている。
【0003】
【発明が解決しようとする課題】
本発明は、優れた細胞賦活効果、美白効果、肌荒れ改善効果、育毛効果を有し、健康上の不安なく使用することができる皮膚外用剤を提供することを目的としてなされたものである。
【0004】
【課題を解決するための手段】
本発明者らは、上記の課題を解決すべく鋭意研究を重ねた結果、植物の胎座の抽出物が動物由来のプラセンタエキスと類似した組成を有し、動物由来のプラセンタエキスと同様な薬効があり、イネ科植物の胎座、特にライ麦の胎座の抽出物が良好であることを見いだし、この知見に基づいて本発明を完成するに至った。
すなわち、本発明は、
(1)イネ科植物の胎座抽出物を含有することを特徴とする皮膚外用剤、及び、
(2)イネ科植物が、ライ麦である第1項記載の皮膚外用剤、
を提供するものである。
【0005】
【発明の実施の形態】
本発明の皮膚外用剤は、植物の胎座抽出物を含有する。本発明に用いる植物の胎座抽出物は、イネ科植物の胎座抽出物であることが好ましく、ライ麦の胎座抽出物であることが特に好ましい。
植物の胎座とは、子房内で胚珠が心皮に付着している部分である。子房は、種子植物の雌蕊の一部で、花柱の下に接して肥大した部分であり、中に胚珠が含まれる。胚珠は、種子植物の雌性生殖器官である。心皮は、種子植物の雌蕊を構成する分化をした葉である。
本発明に用いる植物の胎座抽出物の製造方法に特に制限はなく、例えば、植物の種子から胎座を分離収集し、水溶媒を用いて抽出することができる。種子から分離収集した胎座は、あらかじめ粉砕することが好ましい。胎座を粉砕して微粒化することにより、抽出効率を高めることができる。粉砕された胎座は、1〜15℃の水又は水−エタノール混合液で数時間にわたって数回洗浄することが好ましい。水−エタノール混合液で洗浄することにより、殺菌及び不純物を除去することができる。胎座を洗浄したのち、水を溶媒として抽出を行うことが好ましい。溶媒として用いる水には、0.01〜0.5重量%のパラオキシ安息香酸メチル、フェノキシエタノールなどの防腐剤を添加して、抽出物の変質を防ぐことが好ましい。使用する水溶媒の量に特に制限はないが、抽出液の蒸発残留物が0.05〜10重量%であることが好ましく、0.1〜5重量%であることがより好ましい。
抽出に用いる装置に特に制限はなく、例えば、バッテリー抽出機、ボールマン抽出機、ロトセル抽出機、ルルギ抽出機、ケネディー抽出機などの浸透貫流型固液抽出装置、パチューカタンク、ボノトー抽出機、ヒルデブランド抽出機などの固体分散型固液抽出装置、千代田式L型抽出機、ミアグ抽出機などの貫流浸漬併用型抽出装置などを挙げることができる。抽出に際しては、抽出混合物に超音波を伝達することにより、抽出速度を速めることができる。抽出液は、酸性にして蛋白質を分離することが好ましい。蛋白質を分離した抽出液に、防腐剤、ソルビトール、尿素、クエン酸などを添加して液を調整し、アルカリを添加してpH6〜7とし、孔径0.05〜0.3μmのフィルターで滅菌ろ過することにより、本発明の皮膚外用剤の原料となる植物の胎座抽出物を得ることができる。
【0006】
本発明において、胎座抽出物を取得する植物に特に制限はなく、例えば、イネ科、マメ科、アブラナ科、バラ科、ナデシコ科、サボテン科、アカザ科、コショウ科、ミカン科、キク科、アカネ科、シソ科、ツツジ科などの植物を挙げることができる。これらの中で、イネ科の植物は、大量に栽培されているので入手が容易であり、胎座からの抽出効率が良好なので好適に用いることができる。イネ科の植物としては、例えば、稲、小麦、大麦、ライ麦、燕麦、粟、稗、黍、トウモロコシなどを挙げることができる。イネ科の植物の中で、ライ麦は、胎座の分離収集が容易であり、抽出により多量の胎座抽出物を得ることができるので、特に好適に用いることができる。
本発明の皮膚外用剤は、その用途や剤型によって、適宜必要な成分を配合することができる。このような成分としては、例えば、ラノリン、ミンク油、馬油、アーモンド油、ヒマシ油、ホホバ油、メドフォード油、オリーブ油などの動植物油脂類、コレステリン、ラノリンアルコール、フィトステロールなどの動植物由来のステロール類及びこれらの誘導体、固形パラフィン、セレシン、鯨ロウ、ミツロウ、カルナウバロウなどの鉱物、動植物由来のワックス類、流動パラフィン、スクアランなどの炭化水素油、ラウリルアルコール、セタノール、セトステアリルアルコール、オレイルアルコールなどの高級アルコール類、ラウリン酸、ステアリン酸、オレイン酸などの高級脂肪酸類、ポリオキシエチレンオキシプロピレングリコール、ミリスチン酸イソプロピル、パルミチン酸イソプロピル、イソオクタン酸セトステアリル、イソステアリン酸アルキルエステルなどの合成油、ポリオキシエチレンアルキルエーテル硫酸塩、2−アルキル−N−カルボキシメチル−N−ヒドロキシエチルイミダゾリニウムベタイン、N−ヤシ油脂肪酸アシル−L−グルタミン酸塩などの界面活性洗浄剤類、ポリオキシエチレン高級アルキルエーテル、ポリオキシエチレン高級脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油などの界面活性剤類、グリセリン、ソルビット、プロピレングリコール、1,3−ブチレングリコールなどの多価アルコール類、エタノール、イソプロピルアルコールなどの低級アルコール類、ヒアルロン酸塩、ピロリドンカルボン酸塩、加水分解コラーゲン液などの保湿剤、カチオン化デキストランなどのカチオンリンス剤類、カラギーナン、キサンタンガム、ポリビニルアルコール、カルボキシビニルポリマーなどの増粘剤類、アルニカエキス、アロエエキス、海藻エキス、カモミラエキス、カンゾウエキス、キナエキス、ニンニクエキス、メリッサエキス、アルブチンなどの植物抽出エキス類、アスコルビン酸、アスコルビン酸硫酸エステル、アスコルビン酸リン酸エステル、アスコルビン酸ジパルミテートなどのビタミンC類、コウジ酸、エラグ酸、紫外線吸収剤、酸化防止剤、キレート剤、香料、色素、抗菌剤などを挙げることができる。
本発明の皮膚外用剤の剤型に特に制限はなく、例えば、ローション、クリーム、ジェル、乳液、パック、軟膏などを挙げることができる。
本発明の皮膚外用剤は、優れた細胞賦活機能と美白機能を有する植物の胎座抽出物を含有するので、外傷、火傷、潰瘍などの治療や、皮膚老化防止、美白、育毛などに優れた効果を発揮する。
【0007】
【実施例】
以下に、実施例を挙げて本発明をさらに詳細に説明するが、本発明はこれらの実施例によりなんら限定されるものではない。
なお、実施例及び比較例において、評価は下記の方法により行った。
(1)蒸発残留物
試料1mLを白金るつぼにとり、水浴上で蒸発乾固させたのち、105℃で4時間乾燥し、蒸発残留物を求める。
(2)アミノ酸確認試験1
試料1mLにニンヒドリン試液1mLを加え、3分間煮沸する。
(3)ペプチド確認試験
試料1mLに水酸化ナトリウム試液2mLと硫酸銅溶液(1→100)3滴を加え、振り混ぜる。
(4)アミノ酸確認試験2
試料2mLに硝酸2mLを加えて1分間煮沸し、冷却後アルカリ性になるまで水酸化ナトリウム水溶液を加える。
(5)ワールブルグ法による代謝活性の測定
ラットの肝片にセーレンセン緩衝液(pH7.4)を加えてホモジナイザーで処理したホモジネートを調製し、その酸素消費量をワールブルグ検圧計を用いて測定する。胎座抽出物含有液と対照試料の酸素消費量を算出し、対照試料の呼吸促進係数を1として、胎座抽出物含有液の呼吸促進係数を求める。
(6)メラノーマ細胞試験
試料に牛胎児血清が10重量%になるように加え、炭酸水素ナトリウム水溶液を加えてpH7.6に調整した培地を用い、B−16メラノーマ細胞浮遊液を加えて3日間培養し、さらに培地を交換して3日間培養したのち、遠心分離して細胞を集め、目視により白色度を判定する。
【0008】
実施例1
ライ麦(Secale cereale)の穀粒から、ヤスリを用いて胎座100gを削り取った。削り取った胎座をさらに乳鉢を用いて細かく粉砕し、10重量%エタノール水溶液10,000gにより10℃で10時間回転洗浄した。次に、胎座をろ別し、フェノキシエタノール0.1重量%を溶解した水200gに20℃で10時間浸漬したのち、超音波発振機を用いて周波数40kHz、出力600Wの超音波を60分間伝達した。懸濁液を加圧ろ過し、ろ液に硝酸を加えてpHを2.0に調整し、凝固析出した蛋白質をろ別して、ろ液250gを得た。
得られたろ液にパラオキシ安息香酸メチル0.25gを加えて溶解し、水酸化ナトリウム水溶液によりpHを6.7に調整し、孔径0.2μmのフィルターを用いて滅菌ろ過し、ライ麦の胎座抽出物含有液を得た。
このライ麦の胎座抽出物含有液の蒸発残留物は2.33重量%であり、窒素含量は0.245重量%であった。ライ麦の胎座抽出物含有液に、ニンヒドリン試液を加えて煮沸すると、液は青紫色を呈し、アミノ酸の存在が確認された。水酸化ナトリウム試液と硫酸銅溶液を加えて振り混ぜると、液は赤紫色を呈し、ペプチドの存在が確認された。硝酸を加えて煮沸したのち冷却し、水酸化ナトリウム試液を加えると、液は黄色を呈し、アミノ酸の存在が確認された。ワールブルグ法による呼吸促進作用の測定において、呼吸促進係数は1.8であった。メラノーマ細胞試験の結果は、陽性であった。
比較例1
ブタ胎盤由来のプラセンタエキス[山川貿易(株)]について、実施例1で得られたライ麦の胎座抽出物含有液と同じ試験を行った。
蒸発残留物は0.51重量%であり、窒素含量は0.052重量%であった。ニンヒドリン試液を加えて煮沸すると、液は青紫色を呈し、アミノ酸の存在が確認された。水酸化ナトリウム試液と硫酸銅溶液を加えて振り混ぜると、液は赤紫色を呈し、ペプチドの存在が確認された。硝酸を加えて煮沸したのち冷却し、水酸化ナトリウム試液を加えると、液は黄色を呈し、アミノ酸の存在が確認された。ワールブルグ法による呼吸促進作用の測定において、呼吸促進係数は1.6であった。メラノーマ細胞試験の結果は、陽性であった。
実施例1及び比較例1の結果を、第1表に示す。
【0009】
【表1】
【0010】
第1表に見られるように、実施例1のライ麦胎座抽出物含有液は、すでに商品化されている比較例1のブタ胎盤由来プラセンタエキスに比べて約4.5重量倍の蒸発残留物を含有している。しかし、窒素含料/蒸発残留物の比は、実施例1が0.105、比較例1が0.102で、ほぼ同じ大きさであり、この事実は、実施例1のライ麦胎座抽出物含有液と、比較例1のブタ胎盤由来プラセンタエキスに、ほぼ同種の物質が含有されることを示唆している。2種のアミノ酸確認試験とペプチド確認試験において、実施例1と比較例1で同じ結果が得られている。ワールブルグ法による代謝活性の測定では、実施例1のライ麦胎座抽出物含有液の呼吸促進係数が、比較例1のブタ胎盤由来プラセンタエキスの呼吸促進係数よりやや大きい。B−16メラノーマ細胞試験においては、実施例1、比較例1ともに陽性を示し、両者ともに美白効果を有することが分かる。
実施例2
スクワラン15.0重量部、2−エチルヘキサン酸セチル5.0重量部、オリーブ油5.0重量部、ステアリン酸3.0重量部、ステアリルアルコール3.0重量部、ミツロウ3.0重量部、ポリオキシエチレン(20モル)オキシプロピレン(4モル)セチルエーテル1.0重量部、ポリオキシエチレン(50モル)硬化ヒマシ油1.0重量部、自己乳化型モノステアリン酸グリセリル1.0重量部、メチルポリシロキサン(300cSt)0.2重量部及びパラオキシ安息香酸メチル0.2重量部を配合して、第一成分を調製した。
グリセリン10.0重量部、1,3−ブチレングリコール5.0重量部、実施例1で得られたライ麦胎座抽出物含有液5.0重量部及び精製水42.6重量部を配合して、第二成分を調製した。
第一成分と第二成分をそれぞれ70℃まで加温し、第二成分に第一成分を撹拌しつつ徐々に加えたのち、ゆっくり撹拌しつつ30℃まで冷却して、ライ麦胎座抽出物を含有する皮膚外用剤クリームを得た。
上記と同様にして、第一成分を調製した。また、グリセリン10.0重量部、1,3−ブチレングリコール5.0重量部、比較例1で用いたブタ胎盤由来のプラセンタエキス22.5重量部及び精製水25.1重量部を配合して、第二成分を調製した。
第一成分と第二成分をそれぞれ70℃まで加温し、第二成分に第一成分を撹拌しつつ徐々に加えたのち、ゆっくり撹拌しつつ30℃まで冷却して、ブタ胎盤由来のプラセンタエキスを含有する皮膚外用剤クリームを得た。
年齢20〜64才の女性20名をパネラーとして、ライ麦胎座抽出物を含有するクリームと、ブタ胎盤由来のプラセンタエキスを含有するクリームの官能評価を行った。10名のパネラーには、右前腕部にライ麦胎座抽出物を含有するクリームを、左前腕部にブタ胎盤由来のプラセンタエキスを含有するクリームを、残りの10名のパネラーには、逆に右前腕部にブタ胎盤由来のプラセンタエキスを含有するクリームを、左前腕部にライ麦胎座抽出物を含有するクリームを、3ケ月間にわたって1日2回ずつ塗布した。
3ケ月後、肌のハリの改善、美白効果及び肌への使用感の3項目について、下記の評価基準により5段階の評価を行った。
++:ライ麦胎座抽出物を含有するクリームの方が非常によい。
+:ライ麦胎座抽出物を含有するクリーム方がややよい。
±:両方のクリームの間に差がない。
−:ブタ胎盤由来プラセンタエキスを含有するクリームの方がややよい。
−−:ブタ胎盤由来プラセンタエキスを含有するクリームの方が非常によい。
評価結果をまとめて、第2表に示す。
【0011】
【表2】
【0012】
第2表に見られるように、ライ麦胎座抽出物を含有するクリームとブタ胎盤由来のプラセンタエキスを含有するクリームの間に差がないとするパネラーが最も多かったが、評価の別れたところでは、ライ麦胎座抽出物を含有するクリームの方がよいとするパネラーがやや多く、ライ麦胎座抽出物含有液が、皮膚外用剤の有効成分として、従来より用いられてきたブタ胎盤由来のプラセンタエキスに比べて、勝るとも劣らぬ効果を有することが分かる。
【0013】
【発明の効果】
本発明の皮膚外用剤の有効成分として用いる植物の胎座抽出物は、従来より皮膚外用剤の有効成分として用いられてきた動物の胎盤に由来するプラセンタエキスに比べて同等又はそれ以上の効果を有し、植物に由来する成分であるために、健康上の不安を感じることなく使用することができる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an external preparation for skin. More specifically, the present invention relates to a skin external preparation that has an excellent cell activation effect, whitening effect, rough skin improvement effect, and hair growth effect, and can be used without anxiety about health.
[0002]
[Prior art]
Placenta extract, which is an extract of vertebrate placenta, is known to have remarkable medicinal effects. It is used for skin external preparations such as skin roughening cosmetics, whitening cosmetics, hair cosmetics, and pregnancy line formation inhibitors. In addition to being used as an ingredient, it is also widely known as an ingredient for health drinks and dietary supplements. A placenta extract derived from bovine can be produced, for example, by crushing a placenta of a cow of 3 to 4 months of gestation, centrifuging the extract extracted with water, and performing aseptic filtration. Sold. Placenta extract includes amino acids, peptides, nucleic acids, vitamins and the like.
However, since bovine spongiform encephalopathy (BSE), a so-called mad cow disease, has occurred in Japan, consumers are worried about the use of placenta extract made from animal placenta. Although it is possible to obtain placenta extracts derived from animals other than cattle, such as pigs, it is the consumer's true feeling that it would be desirable to avoid animal-derived ingredients if possible. For this reason, there is a demand for plant-derived drugs that have the same medicinal effects as animal-derived placenta extracts and can be used without health concerns.
[0003]
[Problems to be solved by the invention]
The present invention has been made for the purpose of providing an external preparation for skin that has an excellent cell activation effect, whitening effect, rough skin improvement effect, and hair-growth effect and can be used without worrying about health.
[0004]
[Means for Solving the Problems]
As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that the plant placenta extract has a composition similar to that of an animal-derived placenta extract and has the same medicinal effect as that of an animal-derived placenta extract. The present inventors have found that the extract of the placenta of gramineous plants, in particular, the placenta of rye is good, and based on this finding, the present invention has been completed.
That is, the present invention
(1) a topical skin preparation characterized by containing a placenta extract of a gramineous plant, and
(2) The skin external preparation according to item 1 , wherein the gramineous plant is rye,
Is to provide.
[0005]
DETAILED DESCRIPTION OF THE INVENTION
The external preparation for skin of the present invention contains a plant placenta extract. The placenta extract of the plant used in the present invention is preferably a placenta extract of a gramineous plant, and particularly preferably a placenta extract of rye.
Plant placenta is the part of the ovary where the ovule is attached to the heart skin. The ovary is a part of the pistil of the seed plant, and is an enlarged part in contact with the bottom of the style, and contains an ovule. The ovule is the female reproductive organ of the seed plant. The heart skin is a differentiated leaf that constitutes the pistil of the seed plant.
There is no restriction | limiting in particular in the manufacturing method of the placenta extract of the plant used for this invention, For example, a placenta can be separated and collected from a plant seed, and can be extracted using a water solvent. The placenta separated and collected from the seed is preferably pulverized in advance. Extraction efficiency can be increased by pulverizing the placenta into fine particles. The ground placenta is preferably washed several times over several hours with water at 1 to 15 ° C. or a water-ethanol mixture. Sterilization and impurities can be removed by washing with a water-ethanol mixed solution. After washing the placenta, it is preferable to perform extraction using water as a solvent. To the water used as a solvent, it is preferable to add a preservative such as 0.01 to 0.5% by weight of methyl paraoxybenzoate and phenoxyethanol to prevent the alteration of the extract. Although there is no restriction | limiting in particular in the quantity of the aqueous solvent to be used, It is preferable that the evaporation residue of an extract is 0.05 to 10 weight%, and it is more preferable that it is 0.1 to 5 weight%.
There are no particular restrictions on the apparatus used for extraction, for example, permeation through-flow type solid-liquid extraction devices such as battery extractors, ball man extractors, rotcell extractors, lurgi extractors, Kennedy extractors, pachuca tanks, Bonoto extractors, Hilde extractors. Examples include a solid dispersion type solid-liquid extraction device such as a brand extraction device, a once-through immersion combined type extraction device such as a Chiyoda L-type extraction device and a Miagu extraction device. During extraction, the extraction speed can be increased by transmitting ultrasonic waves to the extraction mixture. The extract is preferably acidified to separate proteins. Preservatives, sorbitol, urea, citric acid, etc. are added to the extract from which the protein has been separated to adjust the solution, and alkali is added to adjust the pH to 6-7, and sterile filtration is performed with a filter having a pore size of 0.05 to 0.3 μm. By doing so, the plant placenta extract used as the raw material of the skin external preparation of this invention can be obtained.
[0006]
In the present invention, there is no particular limitation on the plant from which the placenta extract is obtained, for example, Gramineae, Legumeaceae, Brassicaceae, Rosaceae, Nadesicoceae, Cactiaceae, Rabbitaceae, Pepperaceae, Citrusaceae, Asteraceae, Examples include plants such as Rubiaceae, Lamiaceae, and Azalea. Among these, grasses are cultivated in large quantities, so that they are easily available, and the extraction efficiency from the placenta is good, so that they can be suitably used. Examples of gramineous plants include rice, wheat, barley, rye, buckwheat, straw, straw, straw and corn. Among the gramineous plants, rye can be used particularly preferably because it is easy to separate and collect the placenta and a large amount of placenta extract can be obtained by extraction.
The external preparation for skin of the present invention can be appropriately blended with necessary components depending on its use and dosage form. Examples of such components include animal and plant oils and fats such as lanolin, mink oil, horse oil, almond oil, castor oil, jojoba oil, medford oil and olive oil, and sterols derived from animals and plants such as cholesterol, lanolin alcohol and phytosterol. And derivatives thereof, minerals such as solid paraffin, ceresin, whale wax, beeswax, carnauba wax, waxes derived from animals and plants, liquid oils such as liquid paraffin, squalane, lauryl alcohol, cetanol, cetostearyl alcohol, oleyl alcohol, etc. Higher alcohols, higher fatty acids such as lauric acid, stearic acid, oleic acid, polyoxyethyleneoxypropylene glycol, isopropyl myristate, isopropyl palmitate, cetostearyl isooctanoate, isos Surface activity of synthetic oils such as alkyl acrylate, polyoxyethylene alkyl ether sulfate, 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, N-coconut oil fatty acid acyl-L-glutamate Detergents, surfactants such as polyoxyethylene higher alkyl ether, polyoxyethylene higher fatty acid ester, polyoxyethylene hydrogenated castor oil, polyhydric alcohols such as glycerin, sorbit, propylene glycol, and 1,3-butylene glycol , Lower alcohols such as ethanol and isopropyl alcohol, hyaluronic acid salts, pyrrolidone carboxylates, moisturizing agents such as hydrolyzed collagen liquid, cationic rinsing agents such as cationized dextran, carrageenan, xanthan gum, poly Thickeners such as nyl alcohol and carboxyvinyl polymer, arnica extract, aloe extract, seaweed extract, chamomile extract, licorice extract, kina extract, garlic extract, melissa extract, arbutin and other plant extract extracts, ascorbic acid, ascorbic acid sulfate Vitamin Cs such as esters, ascorbic acid phosphate esters, ascorbic acid dipalmitate, kojic acid, ellagic acid, ultraviolet absorbers, antioxidants, chelating agents, fragrances, pigments, antibacterial agents and the like can be mentioned.
There is no restriction | limiting in particular in the dosage form of the skin external preparation of this invention, For example, a lotion, a cream, a gel, an emulsion, a pack, an ointment etc. can be mentioned.
Since the skin external preparation of the present invention contains a plant placenta extract having excellent cell activation and whitening functions, it is excellent in the treatment of trauma, burns, ulcers, etc., skin aging prevention, whitening, hair growth, etc. Demonstrate the effect.
[0007]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.
In Examples and Comparative Examples, evaluation was performed by the following method.
(1) Take 1 mL of evaporation residue sample in a platinum crucible, evaporate to dryness on a water bath, and then dry at 105 ° C. for 4 hours to obtain the evaporation residue.
(2) Amino acid confirmation test 1
Add 1 mL of ninhydrin reagent to 1 mL of sample and boil for 3 minutes.
(3) To 1 mL of peptide confirmation test sample, add 2 mL of sodium hydroxide test solution and 3 drops of copper sulfate solution (1 → 100) and shake.
(4) Amino acid confirmation test 2
Add 2 mL of nitric acid to 2 mL of sample, boil for 1 minute, and add aqueous sodium hydroxide solution until it becomes alkaline after cooling.
(5) Measurement of metabolic activity by Warburg method A homogenate prepared by adding Selensen buffer (pH 7.4) to a rat liver piece and treating with a homogenizer is prepared, and its oxygen consumption is measured using a Warburg pressure gauge. The oxygen consumption of the placenta extract-containing liquid and the control sample is calculated, and the respiration promotion coefficient of the placenta extract-containing liquid is determined with the respiration promotion coefficient of the control sample being 1.
(6) Add the fetal bovine serum to 10% by weight to the melanoma cell test sample, use a medium adjusted to pH 7.6 by adding aqueous sodium bicarbonate solution, and add B-16 melanoma cell suspension for 3 days After culturing and further culturing for 3 days after changing the medium, the cells are collected by centrifugation, and the whiteness is determined visually.
[0008]
Example 1
100 g of the placenta was shaved from the grain of rye (Secale cereale) using a file. The scraped placenta was further finely pulverized using a mortar and rotationally washed at 10 ° C. for 10 hours with 10,000 g of a 10 wt% ethanol aqueous solution. Next, the placenta is filtered and immersed in 200 g of water in which 0.1% by weight of phenoxyethanol is dissolved at 20 ° C. for 10 hours, and then an ultrasonic wave is transmitted for 60 minutes using an ultrasonic oscillator at a frequency of 40 kHz and an output of 600 W. did. The suspension was filtered under pressure, nitric acid was added to the filtrate to adjust the pH to 2.0, and the coagulated and precipitated protein was separated by filtration to obtain 250 g of a filtrate.
The resulting filtrate was dissolved by adding 0.25 g of methyl paraoxybenzoate, adjusted to pH 6.7 with an aqueous sodium hydroxide solution, sterilized using a 0.2 μm pore size filter, and extracted from rye placenta. A product-containing liquid was obtained.
The evaporation residue of the rye placenta extract-containing liquid was 2.33% by weight, and the nitrogen content was 0.245% by weight. When the ninhydrin test solution was added to the rye placenta extract-containing solution and boiled, the solution was bluish purple, confirming the presence of amino acids. When the sodium hydroxide test solution and the copper sulfate solution were added and shaken, the solution was reddish purple, confirming the presence of the peptide. When nitric acid was added and the mixture was boiled and cooled, and a sodium hydroxide test solution was added, the solution was yellow and the presence of amino acids was confirmed. In the measurement of the respiratory promoting action by the Warburg method, the respiratory promoting coefficient was 1.8. The result of the melanoma cell test was positive.
Comparative Example 1
A placenta extract derived from porcine placenta [Yamakawa Trading Co., Ltd.] was subjected to the same test as the rye placenta extract-containing liquid obtained in Example 1.
The evaporation residue was 0.51% by weight and the nitrogen content was 0.052% by weight. When the ninhydrin test solution was added and boiled, the solution was bluish purple, confirming the presence of amino acids. When the sodium hydroxide test solution and the copper sulfate solution were added and shaken, the solution was reddish purple, confirming the presence of the peptide. When nitric acid was added and the mixture was boiled and cooled, and a sodium hydroxide test solution was added, the solution was yellow and the presence of amino acids was confirmed. In the measurement of the respiratory promoting action by the Warburg method, the respiratory promoting coefficient was 1.6. The result of the melanoma cell test was positive.
The results of Example 1 and Comparative Example 1 are shown in Table 1.
[0009]
[Table 1]
[0010]
As seen in Table 1, the rye placenta extract-containing liquid of Example 1 was about 4.5 times the evaporation residue of the placenta-derived placenta extract of Comparative Example 1 that was already commercialized. Contains. However, the ratio of nitrogen content / evaporation residue was 0.15 for Example 1 and 0.102 for Comparative Example 1, which were about the same magnitude, and this fact is equivalent to the rye placenta extract of Example 1. This suggests that the contained liquid and the placenta-derived placenta extract of Comparative Example 1 contain almost the same kind of substance. In two types of amino acid confirmation tests and peptide confirmation tests, the same results were obtained in Example 1 and Comparative Example 1. In the measurement of metabolic activity by the Warburg method, the respiration promoting coefficient of the rye placenta extract-containing liquid of Example 1 is slightly larger than the respiration promoting coefficient of the placenta-derived placenta extract of Comparative Example 1. In the B-16 melanoma cell test, both Example 1 and Comparative Example 1 are positive, and it can be seen that both have whitening effects.
Example 2
Squalane 15.0 parts, cetyl 2-ethylhexanoate 5.0 parts, olive oil 5.0 parts, stearic acid 3.0 parts, stearyl alcohol 3.0 parts, beeswax 3.0 parts, poly Oxyethylene (20 mol) oxypropylene (4 mol) cetyl ether 1.0 part by weight, polyoxyethylene (50 mol) hydrogenated castor oil 1.0 part by weight, self-emulsifying glyceryl monostearate 1.0 part by weight, methyl A first component was prepared by blending 0.2 part by weight of polysiloxane (300 cSt) and 0.2 part by weight of methyl paraoxybenzoate.
Blending 10.0 parts by weight of glycerin, 5.0 parts by weight of 1,3-butylene glycol, 5.0 parts by weight of the rye placenta extract-containing liquid obtained in Example 1, and 42.6 parts by weight of purified water. A second component was prepared.
The first component and the second component are each heated to 70 ° C., and the first component is gradually added to the second component with stirring, and then cooled to 30 ° C. with slow stirring to obtain the rye placenta extract. The skin external preparation cream containing was obtained.
A first component was prepared in the same manner as described above. Further, 10.0 parts by weight of glycerin, 5.0 parts by weight of 1,3-butylene glycol, 22.5 parts by weight of placenta extract derived from porcine placenta used in Comparative Example 1 and 25.1 parts by weight of purified water were blended. A second component was prepared.
The first component and the second component are each heated to 70 ° C., and the first component is gradually added to the second component while stirring, and then cooled to 30 ° C. with slow stirring to placenta extract derived from porcine placenta A skin external preparation cream containing was obtained.
Using 20 females aged 20 to 64 as panelists, sensory evaluation of a cream containing a rye placenta extract and a cream containing a placenta extract derived from porcine placenta was performed. For 10 panelists, a cream containing rye placenta extract on the right forearm, a cream containing a placenta extract derived from porcine placenta on the left forearm, and for the remaining 10 panelists, on the right A cream containing a placenta extract derived from porcine placenta was applied to the forearm, and a cream containing rye placenta extract was applied to the left forearm twice a day for 3 months.
Three months later, five grades were evaluated according to the following evaluation criteria for the three items of skin firmness improvement, whitening effect, and feeling on the skin.
++: Cream containing rye placenta extract is much better.
+: A cream containing rye placenta extract is slightly better.
±: There is no difference between both creams.
-: A cream containing a placenta extract derived from porcine placenta is slightly better.
-: The cream containing the placenta extract derived from porcine placenta is much better.
The evaluation results are summarized and shown in Table 2.
[0011]
[Table 2]
[0012]
As seen in Table 2, most panelists said that there was no difference between cream containing rye placenta extract and cream containing placenta extract derived from porcine placenta. Some of the panelists said that cream containing rye placenta extract is better, and rye placenta extract-containing liquid is a placenta extract derived from porcine placenta that has been used as an active ingredient for external skin preparations. It can be seen that it has an inferior effect compared to.
[0013]
【The invention's effect】
The plant placenta extract used as an active ingredient of the external preparation for skin of the present invention has an effect equivalent to or higher than that of a placenta extract derived from the placenta of an animal conventionally used as an active ingredient of an external preparation for skin. Because it is a component derived from a plant, it can be used without feeling uneasy about health.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002234713A JP4025600B2 (en) | 2002-08-12 | 2002-08-12 | Topical skin preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002234713A JP4025600B2 (en) | 2002-08-12 | 2002-08-12 | Topical skin preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004075562A JP2004075562A (en) | 2004-03-11 |
JP4025600B2 true JP4025600B2 (en) | 2007-12-19 |
Family
ID=32019442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002234713A Expired - Lifetime JP4025600B2 (en) | 2002-08-12 | 2002-08-12 | Topical skin preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4025600B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101502687B1 (en) | 2013-07-11 | 2015-03-16 | 주식회사 바이오에프디엔씨 | Anti-aging and Anti-inflammatory and Anti-oxidant Cosmetic Composition including Beans Placenta Cell Cultures Extracts |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005027946A1 (en) * | 2003-08-20 | 2005-03-31 | Randolph Riemschneider | Vegetal placenta extracts, method for the production and use thereof |
KR101372789B1 (en) * | 2011-06-07 | 2014-03-12 | 주식회사 바이오에프디엔씨 | Composition for Skin External Application Comprising Culture Extract of Rosa Placenta and Functional Food Comprising the Same |
JP5427921B2 (en) * | 2011-06-07 | 2014-02-26 | 株式会社 銀座・トマト | Skin external preparation composition containing rose culture or extract thereof, method for producing the same, functional food, and antioxidant composition |
KR101619571B1 (en) | 2013-12-03 | 2016-05-10 | 주식회사 바이오에프디엔씨 | Anti-aging Composition for Skin External Application Comprising Magnolia Placenta Culture Extracts |
JP5828355B1 (en) * | 2014-09-22 | 2015-12-02 | 和伎獅子株式会社 | Powdered skin external preparation for hair growth / hair growth and skin condition improvement |
KR101619709B1 (en) | 2015-07-27 | 2016-05-11 | 주식회사 바이오에프디엔씨 | Anti-aging Composition for Skin External Application Comprising Annona squamosa Placenta Culture Extracts |
KR101619712B1 (en) | 2015-07-27 | 2016-05-10 | 주식회사 바이오에프디엔씨 | Anti-aging Composition for Skin External Application Comprising Eupomatia laurina Placenta Culture Extracts |
KR101619711B1 (en) | 2015-07-27 | 2016-05-11 | 주식회사 바이오에프디엔씨 | Anti-aging Composition for Skin External Application Comprising Schizandra chinensis Placenta Culture Extracts |
JP2019019101A (en) * | 2017-07-20 | 2019-02-07 | クラシエホームプロダクツ株式会社 | Skin Cosmetic |
KR102474843B1 (en) * | 2021-11-15 | 2022-12-07 | (주)아모레퍼시픽 | Anti-aging composition and skin external composition compring the same |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6253909A (en) * | 1985-09-02 | 1987-03-09 | Kurooda Japan Kk | Cosmetic containing water-soluble hydrolyzate of vegetable seed protein |
JPH0615450B2 (en) * | 1987-04-08 | 1994-03-02 | 一丸フアルコス株式会社 | Moisturizing ingredient for blending cosmetics consisting of gluten hydrolyzed extract |
JPH05310589A (en) * | 1992-05-15 | 1993-11-22 | Soken Kk | Active oxygen scavenger from cereals |
US5552135A (en) * | 1993-02-25 | 1996-09-03 | Estee Lauder, Inc. | Sunscreens containing plant extracts |
JP3576200B2 (en) * | 1994-05-09 | 2004-10-13 | 共栄化学工業株式会社 | Whitening cosmetics |
JP3486327B2 (en) * | 1996-08-16 | 2004-01-13 | 花王株式会社 | Composition for treating hair and scalp |
JP2000026228A (en) * | 1998-07-10 | 2000-01-25 | Nippon Flour Mills Co Ltd | Collagenase inhibitors, humectants and cosmetics and foods containing them |
FR2783418B1 (en) * | 1998-09-17 | 2000-11-10 | Oreal | ANTI-WRINKLE COMPOSITION COMPRISING A COMBINATION OF TENSIONING POLYMERS OF SYNTHETIC AND / OR NATURAL ORIGIN AND DENDRITIC POLYESTERS |
JP2000256131A (en) * | 1999-03-09 | 2000-09-19 | Kose Corp | Tyrosinase production inhibitor and skin lotion containing the same |
JP2000290134A (en) * | 1999-04-07 | 2000-10-17 | Kanebo Ltd | Bleaching preparation |
JP4063444B2 (en) * | 1999-04-08 | 2008-03-19 | 花王株式会社 | Whitening cosmetics |
JP3995374B2 (en) * | 1999-10-14 | 2007-10-24 | 季一 楠本 | Pepper seed and placenta powder and juice |
JP2001302440A (en) * | 2000-04-17 | 2001-10-31 | Masaaki Okubo | Cosmetic |
-
2002
- 2002-08-12 JP JP2002234713A patent/JP4025600B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101502687B1 (en) | 2013-07-11 | 2015-03-16 | 주식회사 바이오에프디엔씨 | Anti-aging and Anti-inflammatory and Anti-oxidant Cosmetic Composition including Beans Placenta Cell Cultures Extracts |
Also Published As
Publication number | Publication date |
---|---|
JP2004075562A (en) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6324967B2 (en) | ||
JP7275103B2 (en) | Novel cosmetic use of Nephelium lapaceum extract | |
JP4025600B2 (en) | Topical skin preparation | |
JPH06506668A (en) | Use of growth factors in slimming compositions | |
CN114224787A (en) | Composition containing vegetable seed oil and fat and application thereof | |
CN111481475A (en) | Edible lipstick capable of improving female hormone and preparation method thereof | |
JP2015172017A (en) | Anti-skin aging agent containing Shiranui Chrysanthemum extract | |
JP2003176213A (en) | Hair restorer | |
JPS624362B2 (en) | ||
JPH0859450A (en) | External preparation for skin | |
WO2025077900A1 (en) | Moisturizing composition and use thereof | |
JPH05262635A (en) | Dermatic external preparation | |
JP2001288068A (en) | Skin cosmetics | |
JP2011225550A (en) | Matrix metalloprotease production suppressing and elastase activity inhibiting agent | |
JP3596953B2 (en) | Whitening cosmetics | |
JP5711879B2 (en) | Fibroblast growth factor-7 production promoter, scalp / hair cosmetic containing the same, and food and drink | |
JP3650295B2 (en) | Cosmetic raw material derived from pearl oyster | |
JP2000212057A (en) | Cosmetic composition | |
JP4013390B2 (en) | Moisturizing cosmetics | |
JP2005289999A (en) | Cosmetic composition comprising jujube extract and walnut extract | |
JP5855949B2 (en) | Keratin production promoter, hair dye and nail polish | |
JPH09176030A (en) | Medicine for stimulating secretion of sebum | |
WO2022224619A1 (en) | Collagen production enhancer and topical skin agent including same | |
WO2006107184A1 (en) | A pharmaceutical composition for the treatment of atopic dermatitis containing 4-hydroxy-5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)-2-oxiranyl]-1-oxaspiro [2,5]octan-6-one | |
KR20180108251A (en) | Composition for skin improvement containing ligustroflavone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050728 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20061128 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071002 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071005 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4025600 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101012 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111012 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111012 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20161012 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |